Artwork

PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

Jacob Sands, MD - Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes

1:25:15
 
공유
 

Manage episode 336827718 series 103551
PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Go online to PeerView.com/VDU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and can have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity, based on a recent PeerView Live event held during the 2022 ASCO Annual Meeting, focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials will also be highlighted to continue to push for progress in better understanding the biology and expanding the treatment options for SCLC. Upon completion of this activity, participants should be better able to: Describe available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other treatment strategies, as well as emerging prospects in biomarker testing and subtyping that may help guide patient selection for different therapies; Apply the latest evidence and guidelines to incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or through clinical trial enrollment; Implement best practices for diagnosing and managing treatment-related toxicity in patients with SCLC; and Integrate multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC.
  continue reading

413 에피소드

Artwork
icon공유
 
Manage episode 336827718 series 103551
PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Go online to PeerView.com/VDU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and can have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity, based on a recent PeerView Live event held during the 2022 ASCO Annual Meeting, focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials will also be highlighted to continue to push for progress in better understanding the biology and expanding the treatment options for SCLC. Upon completion of this activity, participants should be better able to: Describe available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other treatment strategies, as well as emerging prospects in biomarker testing and subtyping that may help guide patient selection for different therapies; Apply the latest evidence and guidelines to incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or through clinical trial enrollment; Implement best practices for diagnosing and managing treatment-related toxicity in patients with SCLC; and Integrate multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC.
  continue reading

413 에피소드

모든 에피소드

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드